In August 2023, Kenvue (NYSE: KVUE) separated from Johnson & Johnson (J&J), becoming an independent company and joining the ranks of the S&P 500 Dividend Aristocrats. In fact, you are probably familiar with many of Kenvue’s iconic brands—Tylenol, Listerine, BAND-AID, and more—that make this newly independent company the world’s largest pure-play consumer health company by revenue.[1] Moreover, it also inherits Johnson & Johnson’s remarkable 60-year record of dividend growth.
Built on more than a century of heritage, J&J’s former consumer health division has a deep connection with its customers and touches the lives of more than a billion people around the world. Its separation from the pharmaceutical and medical devices segments of J&J enables Kenvue to sharpen its focus and allocate resources efficiently. The result is a leading company in its industry, poised to unlock even greater shareholder value.
Let's not overlook the overall dividend picture. J&J has increased its annual dividends twice since it first announced the separation of Kenvue in 2021.[2] Meanwhile, Kenvue promptly declared its first quarterly dividend,[3] showing that it appears committed to carrying on its six-decade legacy of consistent dividend growth.
Kenvue is a great example of what it means to be a Dividend Aristocrat. Explore all the S&P 500 Dividend Aristocrats Index companies with the ProShares S&P 500 Dividend Aristocrats ETF (NOBL).
[1] Source: Kenvue Corporate Overview.
[2] Source: https://www.jnj.com/johnson-johnson-announces-plans-to-accelerate-innovation-serve-patients-and-consumers-and-unlock-value-through-intent-to-separate-consumer-health-business
[3] Source: Bloomberg.
Learn More
NOBL
S&P 500 Dividend Aristocrats ETF
Seeks investment results, before fees and expenses, that track the performance of the S&P 500® Dividend Aristocrats® Index.